The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Amuvatinib (MP-470), an oral dual inhibitor of mutant kinases and DNA repair: Final results from a 100-patient, 5-arm phase Ib trial in combination with five standard of care (SOC) anticancer regimens.
K. K. Sankhala
Research Funding - SuperGen
A. W. Tolcher
Consultant or Advisory Role - Genentech; SuperGen
Research Funding - Genentech; Ortho Biotech; SuperGen
M. M. Mita
Research Funding - SuperGen
M. S. Gordon
Research Funding - SuperGen
L. S. Rosen
Research Funding - SuperGen
K. P. Papadopoulos
Research Funding - SuperGen
A. Patnaik
Research Funding - SuperGen
R. L. Drengler
Research Funding - SuperGen
A. C. Mita
Research Funding - SuperGen
J. Sarantopoulos
No relevant relationships to disclose
R. G. Bristow
Research Funding - SuperGen
G. Fine
Employment or Leadership Position - SuperGen
Stock Ownership - SuperGen
G. S. Choy
Employment or Leadership Position - SuperGen
Stock Ownership - SuperGen
M. Azab
Employment or Leadership Position - SalerGen
Stock Ownership - SuperGen